| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00774-010-0235-7 |
| P698 | PubMed publication ID | 21063739 |
| P50 | author | Jun-ichi Miyazaki | Q55233932 |
| P2093 | author name string | Kaoru Mori | |
| Hisataka Yasuda | |||
| Yuriko Furuya | |||
| Yoshiya Tomimori | |||
| Tetsuro Enomoto | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Central control of fever and female body temperature by RANKL/RANK | Q24321735 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 | ||
| Efficient selection for high-expression transfectants with a novel eukaryotic vector | Q27860810 | ||
| RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 | ||
| Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody | Q35581843 | ||
| Evidence for the involvement of interleukin 6 in experimental cancer cachexia | Q35602921 | ||
| The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression | Q35883830 | ||
| Current management strategies for hypercalcemia | Q36168196 | ||
| Medical treatment of malignancy-associated hypercalcemia | Q37090051 | ||
| Parathyroid hormone-related protein in hypercalcaemia of malignancy. | Q38773936 | ||
| Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis | Q39124107 | ||
| Constructing adenoviral vectors by using the circular form of the adenoviral genome cloned in a cosmid and the Cre-loxP recombination system | Q40935563 | ||
| A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. | Q41687961 | ||
| Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | Q41723472 | ||
| Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats | Q44773041 | ||
| Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts | Q46413191 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. | Q51703171 | ||
| Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. | Q51788770 | ||
| Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton compared with histology and microcomputed tomography (microCT). | Q53644083 | ||
| Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer | Q68063865 | ||
| Mechanisms of paraneoplastic syndromes of colon-26: involvement of interleukin 6 in hypercalcemia | Q72327484 | ||
| Breast cancer cells interact with osteoblasts to support osteoclast formation | Q73025244 | ||
| Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats | Q74441299 | ||
| Hypercalcemia | Q79836751 | ||
| Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease | Q79984770 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | NF-κB | Q411114 |
| Adenoviridae | Q193447 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 414-421 | |
| P577 | publication date | 2010-11-10 | |
| P1433 | published in | Journal of Bone and Mineral Metabolism | Q15767236 |
| P1476 | title | Establishment of a new murine model of hypercalcemia with anorexia by overexpression of soluble receptor activator of NF-κB ligand using an adenovirus vector | |
| P478 | volume | 29 |
| Q64993249 | RANKL Reduces Body Weight and Food Intake via the Modulation of Hypothalamic NPY/CART Expression. |
| Q37241264 | RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases |
| Q52836861 | The effects of P-gp and CYP450 modulated by rifampicin on the steroid-induced osteonecrosis of the femoral head. |
| Q34583769 | Vitamin D(3) at 50x AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females |
Search more.